In a study aiming to define whether BRAF V600E could represent a suitable marker for melanoma detection, this mutation was identified only in ctDNA from stage III–IV melanoma patients, whereas, in early stages, it was undetectable in the majority of the cases [32]. Here, BRAF is linked to melanoma.